focus -WSS

focus

author：comprehensive 2025-10-03 00:38:05 - browse：2714

Kidney transplants are the most common organ transplant procedure in the U.S., with 25,000 taking place in 2022. But for patients who receive new kidneys, the transplant is often followed by severe lifelong challenges, many of which are linked to the immunosuppression drug regimen required after surgery to ensure the body does not reject the new organ. These treatments have side effects and toxicities that impact patients’ long-term health, and even survival, leading to a transplant failure rate of 30-50% at the 10-year mark.

Now a new trial sponsored by Medeor Therapeutics, the results of which were presented Thursday at the American Society of Nephrology (ASN) Kidney Week 2023 Annual Meeting, offers hope that stem cell therapy may help patients discontinue their immunosuppressant regime within a year of the transplant.

“The ability to get a transplant without being on lifelong immunosuppression is kind of a dream in transplant, so I can see why this would generate a lot of excitement,” said Sommer Gentry, a professor of surgery at New York University, who was not involved in the study and was not at the actual presentation, but reviewed the trial’s presentation slides.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： What does generative AI mean for health care? We asked experts
Next article： Who is Magistrate Judge Moxila Upadhyaya in Trump's Jan. 6 case?

hotspot

WSS

My superpower is killing ticks

White House drug shortage group privately met with industry

Influencer to be charged after chaos erupts in New York City's Union Square

Verily hires former Apple Health leader as chief scientific officer

Global cancer cases to surge 77% by 2050, WHO report says

Vyjuvek, a gene therapy for skin wounds, restored vision in one boy

focus

focus

knowledge

As demand for Covid shots wanes, Moderna seeks its next success

Nearly two

In age of alternative facts, a scholarly course on calling out crap

The drug industry sees a key ally in the Senate prevail

Apple is now the first public company to be valued at $3 trillion

Padmanee Sharma of MD Anderson at center of lawsuit over credit

Heart attack and stroke risk calculators need revising

Updated Covid vaccine has 54% effectiveness, new study suggests

United colonoscopy coverage change 'may cost lives,' doctors say

340B reform proposal comes out of Senate working group

knowledge

A cyberattack has disrupted hospitals and health care in several states

Humana, CVS hope to turn members into patients at clinics

Readout LOUD: Venture capital, Gilead, and more M&A

What Mike Pence has said that could be used in a Donald Trump trial

The drug industry sees a key ally in the Senate prevail

CDC: Uninsured rate hit 'record low' right as states cut Medicaid

hotspot

hotspot

entertainment

entertainment